News MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 10/03/2026 GMT			5-day change	1st Jan Change
2.610 ^USD	-2.61%		-10.77%	-53.97%

03-05	MannKind Reports Convertible Notes Settlement	MT
03-05	Wedbush Adjusts Price Target on MannKind to $8 From $10, Maintains Outperform Rating	MT

All News

03-09	MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026	AQ
03-05	MannKind Reports Convertible Notes Settlement	MT
03-05	MannKind Announces Settlement of Convertible Senior Notes	AQ
03-05	Wedbush Adjusts Price Target on MannKind to $8 From $10, Maintains Outperform Rating	MT
03-04	MannKind to Participate in Upcoming Investor Conferences	AQ
02-27	RBC Downgrades MannKind to Sector Perform From Outperform, Cuts Price Target to $3.50 From $7.50	MT
02-26	Health Care Down Amid Mixed Earnings -- Health Care Roundup	DJ
02-26	MannKind Corporation, Q4 2025 Earnings Call, Feb 26, 2026
02-26	MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-26	MannKind Shares Decline After Q4 Adjusted Earnings Fall	MT
02-26	MannKind Q4 Adjusted Earnings Fall, Revenue Rises	MT
02-26	Earnings Flash (MNKD) MannKind Corporation Reports Q4 Revenue $112.0M, vs. FactSet Est of $97.6M	MT
02-26	Earnings Flash (MNKD) MannKind Corporation Posts Q4 Adjusted EPS $0.01 per Share, vs. FactSet Est of $0.05	MT
02-26	MannKind: Q4 Earnings Snapshot	AQ
02-26	MannKind : Fourth Quarter 2025 Earnings Call Presentation (83e8f5)	PU
02-26	MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
02-19	MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
02-18	MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026	AQ
02-09	MannKind Enrolls First Patient in Study Evaluating Afrezza Inhaled Insulin in Youth	MT
02-09	MannKind announces first patient enrolled in Inhale-1st pediatric study evaluating Afrezza® for youth with newly-diagnosed type 1 diabetes (T1d)	RE
02-09	MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)	AQ
02-09	Mannkind Corporation Announces First Patient Enrolled in Inhale-1St Pediatric Study Evaluating Afrezza®? for Youth with Newly-Diagnosed Type 1 Diabetes	CI
02-08	Lupin Limited Appoints Ms. Christine Mundkur as Independent Director	CI
01-26	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets	AQ
01-26	MannKind Corporation Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance When Switching from Multiple Daily Injections or Insulin Pump Mealtime Therapy	CI